The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor

•CS585 is a novel prostacyclin receptor agonist that effectively inhibits integrin activation, granule secretion, and aggregation.•CS585 is a highly potent and selective compound available both orally and IV and prevents thrombosis between 24 and 48 hours.